Lee Sherlock | Co-Founder & CEO
Meta-Flux

Lee Sherlock is a biochemist and immunologist with research experience across disease indications: cystic fibrosis, oncology small-molecule discovery, and CAR-T cell development. His work spanned early-stage discovery through translational research, focusing on identifying drug targets, evaluating biomarkers, and advancing therapeutic candidates toward clinical readiness. Lee founded Meta-Flux, a Dublin-based tech-bio company developing graph-based, multi-omics simulations to guide drug development. Meta-Flux integrates genomics, proteomics, metabolomics, and transcriptomics into mechanistic disease models that function like an “AI-biologist.” These simulations help R&D teams identify MOA's, predict safety issues, and accelerate preclinical decisions.

Appearances:

Day 2 - Wednesday 15th October @ 13:00

Start-Up Pitches

13:00 - 'Proprietary WISIT Platform Delivers Best-In-Class Parkinson Vaccine'Markus Mandler, CEO & Founder, Tridem Bioscience

13:05 - 'FINVAC: Developing a Universal Intranasal Vaccine Platform'Jenni Vuola, Buisness Development Advisor, Rokote Laboratories Finland

13:10 - 'TITLE TBD'Tom Garnett, CEO & Co-Founder, Refute

13:15 - 'A Modular Versatile Platform for Next-Generation Immunoengineering'Damian Alvarez-Paggi, CEO, Eureka Nanobioengineering

13:20 - 'Beyond the Needle: A Microneedle Platform Delivering Unprecedented Dose Consistency to Accelerate Vaccine Access'Dr. Fazlul-Hoque Chowdhury, Director, C-Mark Bio

13:25 - 'Monitoring the antigen-specific T-cell response with TCR sequencing'Dr. Sander Wuyts, CEO & Co-Founder, ImmuneWatch

13:30 - 'AI-disease simulations: Accelerating Therapeutic Development with Multi-Omics Models'Lee Sherlock, CEO & Co-Founder, Meta-Flux

Jenni Vuola, Business Development Advisor, Rokote Laboratories Finland Oy